Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial

Authors

  • Alonso Soto Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú. Departamento de Medicina, Hospital Nacional Hipólito Unanue, Lima, Perú. Médico internista http://orcid.org/0000-0001-8648-8032
  • Dante M. Quiñones-Laveriano Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú. médico cirujano https://orcid.org/0000-0002-1129-1427
  • Patricia J. García Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Perú. médica cirujana, doctora en Medicina https://orcid.org/0000-0003-3874-2256
  • Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú. médico especialista en Enfermedades Infecciosas y Tropicales
  • Ana María Henao-Restrepo Organización Mundial de la Salud, Ginebra, Suiza. médica epidemióloga http://orcid.org/0000-0001-9910-7999

DOI:

https://doi.org/10.17843/rpmesp.2020.372.5546

Keywords:

COVID-19, SARS-CoV-2, Clinical Trials, Hydroxychloroquine, Remdesivir

Abstract

COVID-19 represents a global crisis. Rapidly conducting a clinical trial with the rigor necessary to obtain reliable results requires the collaboration of various participants involved in the development, evaluation and authorization of clinical trials (CT) such as the trial sponsor, researchers, regulatory authority and the ethics committee (EC). Carrying out these studies is not only scientifically appropriate, but an ethical and moral obligation to guarantee our patients effective treatment. SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy. Peru has joined the list of countries where the trial will be reproduced, through which it will be possible to quickly identify if any of these drugs offers a real benefit to patients

Downloads

Download data is not yet available.

Author Biographies

  • Alonso Soto, Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú. Departamento de Medicina, Hospital Nacional Hipólito Unanue, Lima, Perú. Médico internista

    Profesor. Facultad de Medicina. Universidad Ricardo Palma.

    Jefe del Servicio de Medicina Interna N°1. Departamento de Medicina. Hospital Nacioal Hipólito Unanue

  • Ana María Henao-Restrepo, Organización Mundial de la Salud, Ginebra, Suiza. médica epidemióloga
    Co-Lider del  Projecto de Investigacion y Desarrollo para enfermedades epidémicas (Co-Lead R&D Blueprint)  en el programa  mundial de emergencias de la Organización Mundial de la Salud (WHO Health Emergencies Program, WHE).

Published

2020-05-18

Issue

Section

Special Section

How to Cite

1.
Soto A, Quiñones-Laveriano DM, García PJ, Gotuzzo E, Henao-Restrepo AM. Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial. Rev Peru Med Exp Salud Publica [Internet]. 2020 May 18 [cited 2024 Jun. 18];37(2):356-60. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5546

Most read articles by the same author(s)

<< < 1 2 3 4 5